[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491497":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":55,"collaborators":57,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":20,"enrollmentInfo":78,"targetDuration":20,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"OneChain Immunotherapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: CD1a-CAR T","EXPERIMENTAL","CD1a CAR T cells transduced with a lentiviral vector to express CD1a chimeric receptor domain on T cells administered with a dose-escalation approach.",[13],"Biological: CD1a-CAR T",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CD1a-CAR T","Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Wilmar Castillo","CONTACT","34 93 403 58 62","wilmar@onechaintx.com",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},"Laura Astier","laura.astier@astrumcro.com",[31,46],{"facility":32,"status":33,"city":34,"state":20,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hospital Clínic","RECRUITING","Barcelona","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],2.15899,41.38879,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":20,"phoneExt":20,"email":20},"Nuria Martinez",{"facility":47,"status":33,"city":34,"state":20,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":48,"geoPoint":50,"contacts":51},"Hospital Sant Joan de Déu",{"type":38,"coordinates":49},[40,41],{"lat":41,"lon":40},[52],{"name":53,"role":24,"phone":54,"phoneExt":20,"email":20},"Susana Rives","34 93 280 40 00",{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[58,61,63,65],{"name":59,"class":60},"BioClever 2005 S.L.","OTHER",{"name":62,"class":60},"Hospital Clinic of Barcelona",{"name":64,"class":60},"Hospital Sant Joan de Deu",{"name":66,"class":67},"Astrum CRO, S.L.","UNKNOWN","100491497","phase-1-safety-and-efficacy-of-oc-1-therapy-in-patients-with-rr-t-allll-100491497",false,"NCT05679895","Safety and Efficacy of OC-1 Therapy in Patients With R\u002FR T-ALL\u002FLL","Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed\u002FRefractory (R\u002FR) T-cell Acute Lymphoblastic Leukemia\u002FLymphoma (T-ALL\u002FLL","CARxALL","Inclusion Criteria\n\n1. Children older than 2 years or adults, male and female in both groups.\n2. Patients CD1a antigen blast expression ≥20% at inclusion, either immunophenotypically (flow cytometry) or histologically confirmed.\n3. R\u002FR CD1a-positive T-ALL\u002FLL patients defined as:\n\n   * Failure to achieve morphological complete remission (\\> 5% bone marrow blasts) or persistence of extramedullary disease after at least two cycles of chemotherapy.\n   * First or subsequent relapse, including morphologic or MRD-detectable (≥1x10-4 ) bone marrow and\u002For extramedullary relapses after at least one standard frontline therapy.\n   * Relapse after allogeneic haematopoietic stem cell transplantation (allo-HSCT).\n   * Primary refractoriness, defined as either morphologic persistence or detectable MRD (≥1x10-4 ) after at least two cycles of chemotherapy, making the patient not candidate for allo-HSCT.\n4. Patient without reproductive capacity or else, commitment to the use of a highly effective method of contraception during the study.\n\nExclusion Criteria:\n\n1. Limiting organ dysfunction, such as uncontrolled cardiac (e.g., depressed left ventricular ejection fraction (LVEF), \\\u003C45%), pulmonary, liver, renal or CNS dysfunction.\n2. Allo-HSCT within a time frame \\\u003C3 months, or requiring continued immunosuppressive treatment for graft versus host disease (GvHD).\n3. Uncontrolled epilepsy or underlying central nervous system (CNS) severe disease.\n4. Active bacterial, fungal or viral infection not controlled by adequate treatment.\n5. Known HIV, active hepatitis B (HBV), or hepatitis C virus (HCV) infection.\n6. Women who are pregnant (urine\u002Fblood pregnancy test positive) or lactating.\n7. Severe illness or medical condition, which would not permit the patient to be managed according to the protocol.\n8. Suffering from a serious autoimmune disease or immunodeficiency disease.\n9. The patient participated in other experimental drug clinical trial within 6 weeks prior to OC-1 infusion.\n10. Other non-controlled concomitant neoplasms.","ALL","2 Years",{"count":79,"type":80},20,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed\u002Frefractory (R\u002FR) T-cell acute lymphoblastic leukemia\u002Flymphoma (T-ALL\u002FLL)",[86,87],"T-cell Acute Lymphoblastic Leukemia","Lymphoblastic T-Cell Lymphoma",[89,90],"CAR-T-based therapies","CD1a","2026-03-09",{"date":93,"type":94},"2026-03-11","ACTUAL",{"date":96,"type":94},"2023-01-31",{"date":98,"type":80},"2027-12",{"name":5,"class":6},2]